Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Vaxgen (Anthrax Vaccine Assets and Technology)

M&A STATUS
Asset Purch. LATEST DEAL TYPE
1 FINANCING ROUNDS
Description

Anthrax vaccine program and related assets and technology. The portfolio includes all assets and rights related to a recombinant protective antigen (rPA) anthrax vaccine product.

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Biotechnology
Primary Office
  • 349 Oyster Point Boulevard
  • Suite 10
  • South San Francisco, CA 94080
  • United States

Vaxgen (Anthrax Vaccine Assets and Technology) Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Vaxgen (Anthrax Vaccine Assets and Technology)‘s full profile, request access.

Request full access to PitchBook

Vaxgen (Anthrax Vaccine Assets and Technology) Former Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Vaxgen (Anthrax Vaccine Assets and Technology)‘s full profile, request access.

Request full access to PitchBook